Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 21559449)

1.

Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines.

Boegsted M, Holst JM, Fogd K, Falgreen S, Sørensen S, Schmitz A, Bukh A, Johnsen HE, Nyegaard M, Dybkaer K.

PLoS One. 2011 Apr 29;6(4):e19322. doi: 10.1371/journal.pone.0019322.

2.

Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.

Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE.

PLoS One. 2013 Dec 20;8(12):e83252. doi: 10.1371/journal.pone.0083252. eCollection 2013.

3.

Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.

Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, El-Galaly TC, Bøgsted M, Dybkær K, Johnsen HE; Myeloma Stem Cell Network.

Exp Hematol. 2014 Nov;42(11):927-38. doi: 10.1016/j.exphem.2014.07.263. Epub 2014 Jul 27. Review.

PMID:
25072621
4.

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.

Cancer Res. 2003 Nov 15;63(22):7900-6.

5.

Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

Györffy B, Serra V, Jürchott K, Abdul-Ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R.

Oncogene. 2005 Nov 17;24(51):7542-51.

PMID:
16044152
6.

Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.

McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST.

PLoS One. 2012;7(7):e41455. doi: 10.1371/journal.pone.0041455. Epub 2012 Jul 27.

7.

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.

Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS.

Blood. 2005 Jul 15;106(2):698-705. Epub 2005 Mar 31.

8.

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.

Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS, Beaupre DM.

Clin Cancer Res. 2005 Aug 15;11(16):6057-64.

9.

Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line.

Mutlu P, Ural AU, Gündüz U.

Biomed Pharmacother. 2012 Apr;66(3):228-31. doi: 10.1016/j.biopha.2011.11.023. Epub 2012 Feb 28.

PMID:
22425183
10.

Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM.

Mol Cell Proteomics. 2011 Nov;10(11):M110.005520. doi: 10.1074/mcp.M110.005520. Epub 2011 Aug 16.

11.

Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.

Harada N, Nagasaki A, Hata H, Matsuzaki H, Matsuno F, Mitsuya H.

Acta Haematol. 2000;103(3):144-51.

PMID:
10940652
13.

c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.

Greco C, D'Agnano I, Vitelli G, Vona R, Marino M, Mottolese M, Zuppi C, Capoluongo E, Ameglio F.

Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):67-79.

PMID:
16569345
15.

Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.

Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, Elmore SW, Kroeger PE, Tse C, Rosenberg SH, Anderson MG.

Mol Cancer Ther. 2010 Mar;9(3):545-57. doi: 10.1158/1535-7163.MCT-09-0651. Epub 2010 Feb 23.

16.

Effect of cobalt-60 (γ radiation) on multidrug-resistant multiple myeloma cell lines.

Mutlu P, Baran Y, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, Gündüz U.

Cell Biol Int. 2011 Jul;35(7):721-5. doi: 10.1042/CBI20100061.

PMID:
21241250
17.

Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.

Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N, Sredni B.

Exp Hematol. 2009 May;37(5):593-603. doi: 10.1016/j.exphem.2009.01.006.

PMID:
19375650
18.

Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.

Wallqvist A, Connelly J, Sausville EA, Covell DG, Monks A.

Mol Pharmacol. 2006 Mar;69(3):737-48. Epub 2005 Dec 6.

19.

Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.

Quintieri L, Fantin M, Vizler C.

Adv Exp Med Biol. 2007;593:95-104. Review.

PMID:
17265720
20.

Evidence that aberrant protein metabolism contributes to chemoresistance in multiple myeloma cells.

Sipes RK, Xia X, Lewis BS, Burgis NE.

Oncol Rep. 2012 Jun;27(6):2031-8. doi: 10.3892/or.2012.1716. Epub 2012 Mar 12.

PMID:
22426518
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk